

Fujifilm to invest \$40M in innovative viral vector and advanced therapy facility

January 5, 2021 | News

Establishing a New State-of-the-Art development and manufacturing facility in Massachusetts within the academia and pharma communities



Japan's FUJIFILM Corporation is making a major capital investment of approximately 4 billion yen (\$40 million) in FUJIFILM Diosynth Biotechnologies, a world-leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area. This will be the third location for viral vector CDMO services provided by FUJIFILM Diosynth Biotechnologies.

The new facility is scheduled to begin process development operations in fall 2021 and will expand FUJIFILM Diosynth Biotechnologies' manufacturing capacity to support the growing viral vector sector, which is focused on using genes to treat or prevent disease.

The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.

"The strength of Fujifilm's Bio CDMO business lies in its wide-range of capabilities: process development for a variety of biopharmaceutical such as antibodies, recombinant protein, gene therapy, vaccines, oncolytic virus and more, along with flexible facilities that can adapt to small or large scale manufacturing of drug substances, formulation and packaging," said Takatoshi Ishikawa, senior executive vice president and chief life science officer, FUJIFILM Corporation. "We will continue to leverage our expertise in Bio CDMO to further accelerate our offerings in viral vectors and advanced therapies, with the ultimate goal of fulfilling unmet medical needs."